RTTNews | Jan 5, 2022 08:49AM EST

08:49 Wednesday, January 5, 2022 (RTTNews.com) - F-star Therapeutics Inc. (FSTX) said that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration.

As per the terms of the deal, Merck KGaA will be responsible for all future development and commercialization costs and will pay future success-based milestones and royalties on any net sales, resulting from programs covered by the agreement.

In May of 2019, Merck KGaA exercised its option to bring a first program from the collaboration into its pipeline.

In July 2020, Merck KGaA took an early option to a second program and in March 2021, a third option was exercised.

With the fourth option now exercised, the total potential remaining milestone-based revenue due to F-star from this immuno-oncology collaboration with Merck KGaA is approximately $765 million.

Read the original article on RTTNews ( https://www.rttnews.com/3252953/f-star-therapeutics-merck-kgaa-exercises-fourth-licensing-option-in-immuno-oncology-collaboration.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved